Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction

Journal of Urology

Volumn 157, Issue 6, 1997, Pages 2132-2134

  Bechara, A ^a   Casabe A ^a   Cheliz G ^a   Romano, S ^a   Rey, H ^a   Fredotovich, N ^a  

^a HOSPITAL DURAND   (Argentina)

Author keywords

drug therapy; impotence; papaverine; phentolamine; prostaglandins E

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; IMPOTENCE; PAIN; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030909788     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64694-9     Document Type: Article

References (33)

1. Virag, R.: Intracavernous injection of papaverine for erectile failure. Letter to the Editor. Lancet, 2: 938, 1982.
2. Zorgniotti, A. W. and Lefleur, R. S.: Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J. Urol., 133: 39, 1985.
3. Zorgniotti, A. W.: Corpus cavernosum blockade for impotence: practical aspects and results in 250 cases. J. Urol., part 2, 135: 306A, abstract 808, 1986.
4. Ishii, N., Watanabe, H., Irisawa, C., Kikuchi, Y., Kawamura, S., Suzuki, K., Chiba, R., Tokiwa, M. and Shirai, M.: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J. Urol., 141: 323, 1989.
5. Virag, R. and Shoukry, K.: Long term follow-up on self intracavernous injections (SICI) for impotence. J. Urol., part 2, 141: 288A, abstract 476, 1989.
6. Goldstein, I., Borges, F., Kauffman, J., Moreno, J., Payton, T. and Krane, R. J.: Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin E1. Int. J. Impotence Res., suppl., 2: 277, 1990.
7. Montorsi, F., Guazzoni, G., Bergamaschi, F., Fernini-Strambi, L., Barbieri, L. and Rigatti, P.: Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J. Urol., part 2, 149: 1291, 1993.
8. Bennett, A. H., Carpenter, A. J. and Barada, J. H.: An improved vasoactive drug combination for a pharmacological erection program. J. Urol., 146: 1564, 1991.
9. Juenemann, K.-P.: Pharmacotesting in erectile dysfunction. In: Erectile Dysfunction. Edited by U. Jonas, W. F. Thon and C. G. Stief. New York: Springer-Verlag, chapt. 9, pp. 104-114, 1991.
10. Goldstein, I.: Comment. In: World Book of Impotence Research: Basic and Clinical. Edited by T. F. Lue. London: Smith Jordon & Co., Ltd., chapt. 13, pp. 194-197, 1992.
11. von Heyden, B., Donatucci, C. F., Kaula, N. and Lue, T. F.: Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J. Urol., part 2, 149: 1288, 1993.
12. Wetterauer, U.: Intracavernous pharmacotherapy for erectile dysfunction. In: Erectile Dysfunction. Edited by U. Jonas, W. F. Thon and C. G. Stief. New York: Springer-Verlag, chapt. 19, pp. 221-235, 1991.
13. Katlowitz, N. M., Albano, G. J., Morales, P. and Golimbu, M.: Potentiation of drug-induced erection with audiovisual sexual stimulation. Urology, 41: 431, 1993.
14. Vruggink, P., Debruyne, F. and Meuleman, E.: Enhanced pharmacological testing in erectile dysfunction. Int. J. Impotence Res., suppl. 1, p. D-47, 1994.
15. Donatucci, C. F. and Lue, T. F.: The combined intracavernous injection and stimulation test: diagnostic accuracy. J. Urol., 148: 61, 1992.
16. Lue, T. F. and Tanagho, E. A.: Physiology of erection and pharmacological management of impotence. J. Urol., 137: 829, 1987.
17. Shenfeld, O., Hanani, A., Shalhav, Y. and Goldwasser, B.: Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J. Urol., 154: 1017, 1995.
18. Bechara, A., Casabé, A., Chéliz, G., Romano, S. and Fredotovich, N.: Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J. Urol., 155: 913, 1996.
19. Mulhall, J., Traish, A., Gupta, S., Payton, T., Krane, R. J. and Goldstein, I.: Rescuing the failed injection patient with the use of forskolin. J. Urol., part 2, 155: 496A, abstract 743, 1996.
20. Waldhauser, M. and Schramek, P.: Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J. Urol., 140: 525, 1988.
21. Lee, L. M., Stevenson, R. W. D. and Szasz, G.: Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J. Urol., 141: 549, 1989.
22. Earle, C. M., Keogh, E. J., Wisniewski, Z. S., Tulloch, A. G. S., Lord, D. J., Watters, G. R. and Glatthaar, C.: Prostaglandin E1 therapy for impotence, comparison with papaverine. J. Urol., 143: 57, 1990.
23. Boullier, J. A., Rauscher, J. A., Cummings, J. M. and Parra, R. O.: Comparison of papaverine and prostaglandin E1 (PGE1) single drug therapy for erectile dysfunction. J. Urol., part 2, 156: 468A, abstract 631A, 1996.
24. Gerber, G. S. and Levine, L. A.: Pharmacological erection program using prostaglandin E1. J. Urol., 146: 786, 1991.
25. Mahmoud, K. Z., El Dakhli, M. M., Fahmi, I. M. and Abdel-Aziz, A. A.: Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. J. Urol., 147: 623, 1992.
26. Lakin, M. M., Montague, D. K., VanderBrug Mendendorp, S., Tesar, L. and Schover, L. R.: Intracavernous injection therapy: analysis of results and complications. J. Urol., 143: 1138, 1990.
27. Jueneman, K.: Pharmacotherapy of impotence: where are we going? In: World Book of Impotence Research: Basic and Clinical. Edited by T. F. Lue. London: E. Smith Jordon & Co., Ltd., chapt. 13, pp. 181-188, 1992.
28. Stackl, W., Hasun, R. and Marberger, M.: Intracavernous injection of prostaglandin E1 in impotent men. J. Urol., 140: 66, 1988.
29. Schramek, P., Dorninger, R., Waldhauser, M., Konecny, P. and Porpaczy, P.: Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Brit. J. Urol., 65: 68, 1990.
30. Aboseif, S. R., Breza, J., Bosch, R. J. L. H., Benard, F., Stief, C. G., Stackl, W., Lue, T. F. and Tanagho, E. A.: Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates. J. Urol., 142: 403, 1989.
31. Stief, C. G., Wetterauer, U., Popken, G. and Sommerkamp, H.: Experience with an intracavernous drug delivery system. J. Urol., part 2, 139: 328A, abstract 664, 1988.
32. Sidi, A. A., Cameron, J. S., Dykstra, D. D., Reinberg, Y. and Lange, P. H.: Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury. J. Urol., 138: 539, 1987.
33. Abobakr, R. A., Mulhall, J., Goldstein, B., Leitzes, R., Woods, J., Payton, T., Krane, R. J. and Goldstein, I.: The prevalence and causes of patient drop-out from long-term self-injection therapy for impotence: survey results from 708 respondents. J. Urol., part 2, 155: 469A, abstract 632, 1996.